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ABSTRACT
Collagens are the most abundant ﬁbrous protein in the human body and constitute the main
structural element of the extracellular matrix. It provides mechanical and physiological support for
cells. In the pancreas, collagen VI content is more than double that of collagen I or IV. It is a major
component of the islet-exocrine interface and could be involved in islet-cell survival. To test the
impact of collagen VI on human encapsulated pancreatic islets-cells, we tested the effects of
exogenous collagen type VI on in vitro functional survival of alginate encapsulated human islet-
cells. Concentrations tested ranged from 0.1 to 50 mg/ml. Islets in capsules without collagen type VI
served as control. Islet-cell interaction with collagen type VI at concentrations of 0.1 and 10 mg/ml,
promoted islet-cell viability (p<0.05). Although no improvement in glucose induced insulin
secretion (GSIS) was observed, islets in capsules without incorporation of collagen type VI showed
more dysfunction and oxygen consumption rates was improved by inclusion of collagen type VI.
Our results demonstrate that incorporation of collagen type VI in immunoisolated human islets








Islet transplantation is a promising method to cure
patients with type I diabetes. Transplantation of alloge-
neic pancreatic islets can theoretically regulate glucose
levels from a minute-to-minute level,1,2 preventing the
development of hypoglycemia and diabetic complica-
tions.3 An advantage of implanting pancreatic islets
over transplantation of the whole pancreas is that iso-
lated islets can be modulated before transplantation to
reduce the risk of graft rejection.4,5 Moreover, islet
transplantation is a minimal invasive surgical proce-
dure with short hospitalization periods and can be
repeated in cases of graft failure with minor adverse
effects.1,6 Isolated islets can also be enveloped in immu-
noisolating capsules that are impermeable to immuno-
globulins and cells of the immune system but allow
diffusion of nutrients, glucose, and insulin.6-8 This
could potentially lead to avoidance of the need to
administer immunosuppressive drugs, which cause
unwanted side-effects.9,10 This technology of immunoi-
solation is subject of intense research, as it would make
islet-transplantation available for a larger group of
patients with type I diabetes.6,11
The proof of principle application of encapsulated
islets for the treatment of type I diabetes has been
shown in several studies in both experimental animals
and in humans,12,13 however, islet graft survival is still
never permanent and in most cases limited to several
months.14 A factor considered to inﬂuence the dura-
tion of graft survival is the loss of interaction with the
extracellular matrix (ECM) in isolated islets.2,15-17 As
a consequence of islet-isolation, the ECM molecules
that surround the islets and interconnect the endo-
crine cells in the pancreatic islets are damaged by
application of collagenases.2,16,18,19 This enzymatical
isolation process impacts laminins as well as collagen
type I, III, IV, V and VI in islets.20 Moreover, recently
it has been shown that after isolation with ECM-
degrading collagenases, the whole microvasculature of
the islet is destroyed,20 and that pancreatic islet-cells
undergo different cell death processes such as anoikis,
necroptosis, and necrosis.18,19,21,22
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A strategy of supplementation of islets with ECM
molecules has been shown to enhance functional sur-
vival of encapsulated pancreatic islets.23-25 Incorpo-
ration of ECM guides cellular development by
mimicking the biochemical composition of ECM in
the target organ, its ﬁbrillar structure, and its visco-
elastic properties.26 Examples of molecules that are
considered to enhance survival of islets are laminins
and collagens.27 Laminin may beneﬁt islet-survival by
modulating the expression of speciﬁc transcription
factors and hormones such as Pdx-1, insulin 1 and
insulin 2, glucagon, somatostatin, and GLUT-2.28
Moreover, different adhesive laminin sequences such
as IKVAV, VAYI, and IKLLI, YIGSR, PDSGR, located
in a1 and b1chain have been shown to inﬂuence pan-
creatic islet-cell function.29,30
The most essential collagens used as supplement or
adjuvant for cellular functions in biomedical applica-
tions are collagens type I and IV.31,32 Collagen is pres-
ent and located in the islet–exocrine interface and
basement membrane of islets where it regulates ﬁbro-
nectin assembly by restraining cell–ﬁbronectin inter-
actions.33-35 In contrast to collagen type IV, effects of
collagen type VI on islet-survival and function has not
been studied. Collagen type VI is composed of three
polypeptide chains that form a short triple helix.
These polypeptide chains are named a1 (VI), a2 (VI),
and a3 (VI), and are encoded by three genes.36 The
importance of collagen type VI for tissue homeostasis
is illustrated by the observation that a deﬁciency of
collagen type VI results in death of muscle cells caus-
ing muscular dystrophy.37 Since collagen type VI is
abundantly present in the pancreas,38,39 we investi-
gated the effect of exogenous collagen VI on islet-cell
survival and function.
The goal of this study was to investigate the effect of
collagen type VI on the functional survival of human
pancreatic islets in immunisolating alginate-based
capsules. Functional survival of islets was studied by
determining the glucose stimulated insulin secretion
(GSIS) and the oxygen consumption rate (OCR) in




Human islets were obtained from Prodo Laboratories
Inc. (Irvine, USA). A dithizone (Merck, USA) staining
was performed before shipment to determine the
purity. Islets with a purity over 80% were shipped to
the Groningen University Medical Center (Groningen,
The Netherlands). Immediately after arrival, islets
were washed before handpicking and cultured in
CMRL medium (Gibco, USA), supplemented with
10% fetal calf serum (FCS), 1% penicillin/streptomy-
cin (Gibco, USA), 1% glutamax (Gibco, USA), 2%
HEPES (Gibco, USA), and 8.3 mM D-glucose (Sigma-
Aldrich, USA. Before encapsulation, islets were both
micro- and macroscopically inspected. After encapsu-
lation islets were tested for glucose stimulated insulin
secretion (GSIS) and subjected to live-dead staining
kit for mammalian cells to conﬁrm viability and func-
tion. Human islets were cultured in a humidiﬁed 5%
CO2 incubator at 37C.
Microencapsulation
Capsules were composed of puriﬁed 3.4% intermedi-
ate-G alginate (44% G-chains, 56% M-chains, 23%
GG-chains, 21% GM-chains, 37% MM-chains), mixed
with collagen type VI (Abcam, UK) by physical
entrapment in concentrations of 0.1, 10, and 50 mg/
ml. Capsules without type VI collagen served as con-
trols. An air-driven droplet generator was used for the
encapsulation of human islets.40,41 Before encapsula-
tion, per donor, islets were split up in different appro-
priate portions and mixed with 3.4% ultrapure
alginate containing either 0.1, 10, or 50 mg/ml collagen
VI. The alginate was puriﬁed as previously described42
and tested for presence of endotoxins.43,44 Islets were
mixed in a ratio of 1000 islets/ml alginate and trans-
ferred into droplets45,46 and collected in 100 mM
CaCl2. Droplets were gelled in 100 mM CaCl2 solution
for at least 10 minutes.47 The diameters of the droplets
were between 500–650 mm. All droplets were washed
with KRH buffer containing 2.5 mM CaCl2 for
2 minutes. Subsequently, encapsulated islets were cul-
tured in CMRL 1066 (Gibco, USA) supplemented
with 8.3 mM D-glucose, penicillin/streptomycin (1%)
(Gibco, USA), and 10% fetal calf serum (FCS) (Gibco,
USA) at 37 C, 5% CO2 till further use.48-50
Glucose-stimulated insulin secretion of encapsulated
islets
Human pancreatic islets were tested for GSIS at days
3, 5, and 7. The production of insulin was measured in
response to low and high glucose solutions. Twenty-
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ﬁve encapsulated islets were transferred to glass incu-
bation tubes. The ﬁrst incubation consisted of a low
glucose concentration solution in KRH (2.75 mM) for
1 hour, followed by a high glucose concentration
buffer in KRH (16.7 mM) for 1 hour, and another 1-
hour incubation in 2.75 mM glucose in KRH. At the
end of each incubation, the incubation media were
removed and frozen for insulin measurement via
Enzyme-Linked Immunosorbent Assay (ELISA)
(Mercodia AB, Sweden) using a spectrophotometric
plate reader as previously described.41 Finally, insulin
concentrations were calculated through the interpola-
tion of sample absorbance values from the standard
curves.
DNA content of islets was quantiﬁed with a ﬂuores-
cent Quant-iT PicoGreen double-strand DNA
(dsDNA) assay kit (Invitrogen, United States). The
insulin secretory responses were expressed as a nano-
gram of insulin.ml¡1. mDNA¡1. hour¡1.
Live/dead cell viability assay
Viability of the encapsulated islets was tested using a
LIVE/DEAD Cell Viability/Cytotoxicity Assay Kit
(Thermo Scientiﬁc). Encapsulated islets were incu-
bated in culture media with Calcein AM (1 mM) and
Ethidium homodimer (EthD) (2 mM) (concentration
according to manual) for 30 minutes in the dark. After
the incubation period, islets were washed with 25 mM
KRH buffer, pH 7.4 prior to imaging.
A helium-neon and an argon-krypton laser were
used in combination with a confocal microscope
(Leica) to quantify islet-cell viability at days 3, 5, and 7.
The data was analyzed in ImageJ (v1.48b; National
Institutes of Health), and viable or dead cells was
expressed as the percentage the total number of stained
cells. Imaris 664 version 7.6.4 software was applied.45
Islet oxygen consumption
The oxygen consumption rate (OCR) was measured
using an XF24 Extracellular Flux Analyzer (Seahorse
Bioscience, USA).51 This experiment was performed
at 72 hours after encapsulation and for one-time point
only as the assay requires the use of high numbers of
islets. To perform OCR, human islets were retrieved
from the capsules by dissolving the capsules in 25 mM
citrate solution at 37C. The islets were transferred to
6-well plates, and fresh medium was added before put-
ting the plate at culture conditions. After that, human
islets were transferred to the microplate reader pro-
vided with the XF24 Islet FluxPak (Seahorse Biosci-
ence, USA). For the correct measurement, at least 80
islets were inserted in every well of the XF24 islet cap-
ture microplate. Experiments were performed in
triplo. The islets were centered in the wells and a
screen was ﬁxed upon each islet-containing well. The
medium was removed and the islets were washed
3 times with MA medium (XF assay media) and incu-
bated for 60 minutes at 37C. After addition of 500 ml
of MA medium, the plate was placed into the XF24
Extracellular Flux Analyzer. At the end of the experi-
ment, islets were transferred to Eppendorf cups and
stored at ¡20C for DNA content analysis. OCR data
was normalized for DNA content to allow for compar-
ison of different experimental conditions and adjust
for the variation in islets numbers. Oxygen consump-
tion rate was expressed as minutes OCR/DNA (pmol
O2¢min–1¢mg–1 DNA) and analyzed by Seahorse XF24
software. An initial drift in OCR was typically
observed in the ﬁrst 1–2 measurements. Analysis
started at an interval of 5–8 minutes after steady state
was reached.
Statistical analysis
Results were expressed as a mean § standard error of
the mean (SEM). A Two-way ANOVA followed by
Tukey’s secondary tests for signiﬁcance was used for
GSIS, stimulation index and live-dead staining data.
Paired t-test was applied in order to evaluate the OCR.
The analysis was performed using GraphPad Prism
5.0 (GraphPad Software, USA). A value of p < 0.05
was considered statistically signiﬁcant.
Results
Effect of collagen type VI on GSIS on encapsulated
human islets
We investigated the effect of collagen type VI on islet-
cell functionality and survival, as collagen type VI is
an ECM component and basement membrane (BM)
anchoring molecule in human islets.35,52 To this end,
collagen VI was incorporated into islet-containing
alginate microcapsules. We tested the effects of 0.1,
10, and 50 mg/ml on GSIS of human islets encapsu-
lated in alginate at days 3, 5, and 7. The GSIS data for
encapsulated islets with and without collagen type VI
is shown in Fig. 1. GSIS was not statistically inﬂuenced
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by collagen type VI addition, but there was a trend
toward higher GSIS in encapsulated islets with 10 mg/
ml and 50 mg/ml at day 7.
Interestingly, stimulation index of pancreatic islets
entrapped with 10 mg/ml collagen type VI was signiﬁ-
cantly higher (p < 0.05) than that of control groups
(Fig. 2). The glucose stimulation index signiﬁcantly
increased 1.8 and 2.3 time-fold at day 5 and 7 for islets
encapsulated in alginate with 10 mg/ml collagen type
VI (p < 0.05).
Collagen type VI improves cell viability of human
islets
Despite the absence of statistically signiﬁcant effects
on GSIS, we did ﬁnd signiﬁcant effects of collagen
type VI incorporation on the viability of encapsulated
pancreatic islets, as shown in Fig. 3b. From day 3 of
culture and onwards, cell-survival enhancing effects of
collagen type VI were observed. At day 5, all the tested
groups containing collagen type VI had strong and
statistically signiﬁcant effects on islet-cell viability
(p < 0.01). The percentage of surviving cells was 87.7
§ 6.1%, 86.5 § 2.4% and 85.6 § 1.9% (p < 0.01),
when collagen type VI at 0.1, 10 and 50 mg/ml were
added to the alginate matrix respectively. Moreover, a
signiﬁcant increase of 11% on islet viability was
observed in encapsulated islets entrapped with 10 mg/
ml collagen type VI at day 7. Although, no differences
between higher collagen VI concentrations at any
time-point was observed, in general, the strongest and
most persistent effects were observed with encapsu-
lated islets containing 10 mg/ml collagen type VI
(p < 0.05).
Interestingly, islet-containing capsules with colla-
gen type VI showed a diminished cell death trend
compared to controls during the culture days
(Fig. 3c). Although, not statistically signiﬁcant at day
3, all tested groups containing collagen type VI dem-
onstrated a trend to inhibition of cell death. At day 5,
pancreatic islets entrapped with 0.1 mg/ml collagen
type VI have shown a 16 § 7.6% on death cells rate,
presenting a decrease of 12.2% when compared to cap-
sules without collagen type VI (p < 0.05).
Oxygen consumption rate analysis
The effect of collagen VI on oxygen consumption rate
(OCR) of islet-cells was tested only at 72h of culture
because we needed to use relatively high amounts of
islets. The addition of collagen type VI does enhance
Figure 1. Glucose induced insulin secretion (GSIS) of human islets
encapsulated in alginate-based capsules supplemented with col-
lagen VI. Concentrations of 0.1, 10 and 50 mg/ml collagen VI
tested at day 3 (a), 5 (b) and 7 (c). The bars from left to right indi-
cate insulin production upon incubation with low (2.75 mM),
high (16.7 mM), and low glucose solution of sets of 25 pancreatic
human islets for each condition. Values represent mean § SEM
(n D 4, different donors).
Figure 2. The ﬁgure shows the stimulation index (SI) of encapsu-
lated islet in response to low (2.75 mM), and high (16.7 mM) glu-
cose. Results from human islets encapsulated in alginate-based
capsules supplemented with collagen VI at concentrations of 0.1,
10 and 50 mg/ml collagen VI tested at day 3, 5 and 7. Error bars
represent standard error. Statistical signiﬁcance is indicated by
stars (p < 0.05).
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OCR but this only reached statistically signiﬁcant dif-
ferences when applying 0.1 mg/ml (p < 0.01) and
10 mg/ml (p < 0.05). The oxygen consumption rate
gives an indication of the viability and functionality of
the islets and correlates with graft survival after
implantation.53,54 As shown in Fig. 4, islets encapsu-
lated in 0.1 mg/ml collagen type VI had an OCR of
769.07 § 82.9 pmol O2¢min–1¢mg–1 DNA which was
nearly two-fold higher than the OCR of the control
group (p < 0.01). OCR of islets entrapped with 10 mg/
ml collagen type VI was 1.5 fold higher than the con-
trol group (p < 0.05). Additionally, there was a trend
towards higher OCR using higher concentrations of
collagen type VI.
Discussion
Various ECM molecules have shown to enhance the
survival of islets. Examples of these molecules are
laminin and several collagens.27 Collagens type I and
type IV have been studied extensively for their role in
enhancing survival of pancreatic islet-cells2,55 but col-
lagen type VI has not been studied yet. Collagen type
VI is expressed in human connective tissues, and in
some specialized regions such as the pancreas islet–
exocrine interface,35 but its presence in the basement
membrane is less recognized.52 Just like other collagen
types in islets, collagen VI is structurally damaged and
digested during the enzymatic isolation process of
islets from the pancreas.20 To the best of our knowl-
edge, this study is the ﬁrst to demonstrate the beneﬁ-
cial effects of collagen type VI on functional survival
of human islets. Collagen type VI can provide advan-
tages over other types of ECM, as collagen type VI is
the predominant constituent subtype immediately
surrounding islets in the pancreas.38 Previous studies
have shown that collagen type VI is present in the
peri-islet capsule in the porcine pancreas,33 whereas
Figure 3. Live/dead staining of human islet-cells encapsulated in alginate-based capsules containing either 0.1, 10, and 50 mg/ml colla-
gen type VI. Illustration of islets in control condition (in alginate capsule without collagen), and a capsule containing 10 mg/ml collagen
VI (a). Islet-cell viability was enhanced by inclusion of collagen VI in the immunoprotective capsule at all-time points tested (b). Encapsu-
lated human islets were stained with ethidium homodimer-1 to quantify the percentage of dead cells at days 3, 5, and 7 of culture (c).
Alginate capsules without ECM components served as control. Values represent mean § SEM (n D 4, different donors). , and  indi-
cates statistical signiﬁcant differences (p < 0.05), and (p < 0.01) when compared to control islets respectively (Col VI, collagen type VI).
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collagen type I, III, and IV are expressed predomi-
nantly in the peri-islet region.56
Although not statistical signiﬁcant, effects on GSIS
were found. We observed signiﬁcant survival enhancing
effect of up to 20% when collagen type VI was incorpo-
rated in the alginate-based capsules. In addition, beneﬁ-
cial, enhancing effects were observed on OCR. The
latter is an important measure for viability after implan-
tation as higher OCR values correlate with higher graft
survival rates after implantation.54 OCR represents the
metabolic responsiveness of the islets, and correlates
better with functionality of the graft than GSIS.54 Nota-
bly, our results are obtained with islet-preparations
with minimal donor-variations in viability. Results may
be different with islet-sources of lower quality or prepa-
rations where larger donor-variability is present. In all
cases however collagen VI may enhance viability.
Higher concentrations of collagen type VI were
associated with a negative impact on survival of islet-
cells. A similar concentration dependent effect on
islet-OCR has been reported for collagen type IV.2
This can be explained by the fact that supraphysiologi-
cal collagen concentrations diminish metabolic capac-
ity such as insulin release.2,23,57 Negative effects of too
high collagen concentrations have also been reported
in cancer studies. Tumor-promoting effects of supra-
physiological high concentrations of collagen type VI
were observed,58 suggesting that increased concentra-
tions enhance cell survival at the expense of cell func-
tioning. Thus, increasing the concentration of type VI
collagen beyond the tissue-concentration could induce
toxicity and negatively impact islet-cell survival.2,57-59
The effect of collagen VI on islet-cell survival is differ-
ent from that of collagen IV. Collagen IV impacted
both GSIS and viability while collagen VI only impacts
viability. Collagen IV enhanced GSIS in a concentra-
tion dependent fashion and was most effective at a
concentration of 50 mg/ml.2,25 The positive effect on
viability was similar for the two collagen types.
We recently have shown that inclusion of ECM is
an efﬁcacious strategy to promote islet-cell survival
after isolation of human islets from the pancreas.2,57
Here we have focused on the efﬁcacy of collagen type
VI. We show it has a positive impact on islet-cell
viability. It did not inﬂuence GSIS but did enhance
cell-survival and OCR. Moreover, as collagen VI spe-
ciﬁcally stimulates the cell death inhibitor b1 integrin
it is probably this interaction that is partly responsible
for the beneﬁcial effect of collagen VI on islet-cell sur-
vival. However, as ECM act in concert with other col-
lagens and laminins it might also be that addition of
collagen VI to the intracapsular environment contrib-
utes to re-assembly of the ECM islet-network and by
that contributes to prevention of cell death. A third
explanation is that islet-isolation is associated with
release of deleterious cytokines that damage islet-cells
in an auto- or paracrine fashion.18 Addition of ECM
might reduce cytokine susceptibility of islets57 and
thereby contribute to better survival of islet-cells.57
Which ECM components is most effective in support-
ing these beneﬁcial effects is still subject of investiga-
tion.2,57,59 In previous studies, we have shown that the
interaction and beneﬁcial effects of ECM of islets is
highly ECM dependent and even concentration
dependent.2,57 Our current study extends these inves-
tigations and show that collagen VI contributes to sur-
vival of islet-cells after isolation from the pancreas.
Conclusions
Not all but only a few ECM molecules support func-
tion and survival of human pancreatic islet-cells in
alginate-based microcapsules applied for immunopro-
tection of islets.2 Here we show that collagen VI is one
of these survival promoting ECM molecules. Incorpo-
ration of 0.1 to 10 mg/ml collagen type VI in the
Figure 4. Oxygen consumption rate (OCR) of human islets encap-
sulated in alginate capsules containing a combination of 0.1, 10
or 50 mg/ml after 72 hours in culture. OCR was expressed after
correction for DNA content (OCR/DNA). Values represent mean §
SEM. , and  indicates statistical signiﬁcant differences (p <
0.05), and (p < 0.01) when compared to control islets respec-
tively (n D 4, different donors).
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alginate-capsule microenvironment promotes islet-cell
viability. The present data underscore that the intra-
capsular environment should receive more attention
in effort to support longevity of encapsulated islet.
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